Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Alzheimer's Disease

  Free Subscription


23.12.2024

1 Acta Neuropathol
5 Alzheimers Dement
1 Am J Alzheimers Dis Other Demen
3 Am J Geriatr Psychiatry
2 BMC Neurol
1 BMJ
3 Brain
2 Brain Res
1 Curr Alzheimer Res
1 Dement Geriatr Cogn Disord
2 Exp Gerontol
1 Exp Neurol
13 J Alzheimers Dis
1 J Biol Chem
6 J Neurochem
3 J Neurol
2 J Neurol Neurosurg Psychiatry
1 J Neurosci
1 Lancet Neurol
1 Nat Med
1 Nature
2 Neurobiol Aging
1 Neurochem Res
4 Neurology
4 Neuroscience
6 PLoS One
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Acta Neuropathol

  1. KADAMANGUDI S, Marcatti M, Zhang WR, Fracassi A, et al
    Amyloid-beta oligomers increase the binding and internalization of tau oligomers in human synapses.
    Acta Neuropathol. 2024;149:2.
    PubMed         Abstract available


    Alzheimers Dement

  2. READHEAD BP, Mastroeni DF, Wang Q, Sierra MA, et al
    Alzheimer's disease-associated CD83(+) microglia are linked with increased immunoglobulin G4 and human cytomegalovirus in the gut, vagal nerve, and brain.
    Alzheimers Dement. 2024 Dec 19. doi: 10.1002/alz.14401.
    PubMed         Abstract available

  3. SILVA JF, Polk FD, Martin PE, Thai SH, et al
    Sex-specific mechanisms of cerebral microvascular BK(Ca) dysfunction in a mouse model of Alzheimer's disease.
    Alzheimers Dement. 2024 Dec 19. doi: 10.1002/alz.14438.
    PubMed         Abstract available

  4. ELHAGE A, Cohen S, Cummings J, van der Flier WM, et al
    Defining benefit: Clinically and biologically meaningful outcomes in the next-generation Alzheimer's disease clinical care pathway.
    Alzheimers Dement. 2024 Dec 19. doi: 10.1002/alz.14425.
    PubMed         Abstract available

  5. ZHOU X, Cao H, Jiang Y, Chen Y, et al
    Transethnic analysis identifies SORL1 variants and haplotypes protective against Alzheimer's disease.
    Alzheimers Dement. 2024 Dec 10. doi: 10.1002/alz.14214.
    PubMed         Abstract available

  6. LANSDALL CJ, Cummings JL, Andrews JS
    Appropriate use of meaningful within-patient change (MWPC) thresholds in Alzheimer's disease.
    Alzheimers Dement. 2024 Dec 18. doi: 10.1002/alz.14436.
    PubMed        


    Am J Alzheimers Dis Other Demen

  7. TIWARI VK, Indic P, Tabassum S
    A Study on Machine Learning Models in Detecting Cognitive Impairments in Alzheimer's Patients Using Cerebrospinal Fluid Biomarkers.
    Am J Alzheimers Dis Other Demen. 2024;39:15333175241308645.
    PubMed         Abstract available


    Am J Geriatr Psychiatry

  8. AGA VM
    Brexpiprazole for the Treatment of Agitation in Alzheimer's Disease Dementia: Clinical Uncertainties and the Path Forward.
    Am J Geriatr Psychiatry. 2024 Nov 19:S1064-7481(24)00533.
    PubMed         Abstract available

  9. LEE H, Kim BH, Lee EH, Shin D, et al
    Brain Metabolic Resilience in Alzheimer's Disease: A Predictor of Cognitive Decline and Conversion to Dementia.
    Am J Geriatr Psychiatry. 2024 Dec 3:S1064-7481(24)00543.
    PubMed         Abstract available

  10. MOREHOUSE CR, Hendriks S, Rabbee N, Kim SY, et al
    Do Caregivers Value the New Antiamyloid Treatments for Alzheimer's Disease More Than Home-Based Care?
    Am J Geriatr Psychiatry. 2024 Nov 26:S1064-7481(24)00541.
    PubMed         Abstract available


    BMC Neurol

  11. SIRIPAOPRADIT Y, Chatsirisakul O, Ariyapaisalkul T, Sereemaspun A, et al
    Exploring the gut-brain axis in alzheimer's disease treatment via probiotics: evidence from animal studies-a systematic review and meta-analysis.
    BMC Neurol. 2024;24:481.
    PubMed         Abstract available

  12. DEVULDER A, Vanderlinden G, Cleeren E, Goovaerts V, et al
    A case report about focal status epilepticus as first presentation in Alzheimer's disease: finding the culprit.
    BMC Neurol. 2024;24:478.
    PubMed         Abstract available


    BMJ

  13. R PATEL V, Liu M, Worsham CM, Jena AB, et al
    Alzheimer's disease mortality among taxi and ambulance drivers: population based cross sectional study.
    BMJ. 2024;387:e082194.
    PubMed         Abstract available


    Brain

  14. LEE SH, Bae EJ, Perez-Acuna D, Jung MK, et al
    Amyloid-beta-activated microglia can induce compound proteinopathies.
    Brain. 2024;147:4105-4120.
    PubMed         Abstract available

  15. WANG D, Honnorat N, Toledo JB, Li K, et al
    Deep learning reveals pathology-confirmed neuroimaging signatures in Alzheimer's, vascular and Lewy body dementias.
    Brain. 2024 Dec 9:awae388. doi: 10.1093.
    PubMed         Abstract available

  16. PILOTTO A, Quaresima V, Trasciatti C, Tolassi C, et al
    Plasma p-tau217 in Alzheimer's disease: Lumipulse and ALZpath SIMOA head-to-head comparison.
    Brain. 2024 Dec 16:awae368. doi: 10.1093.
    PubMed         Abstract available


    Brain Res

  17. DE SOUSA RAL, Mendes BF
    T-regulatory cells and extracellular vesicles in Alzheimer's disease: New therapeutic concepts and hypotheses.
    Brain Res. 2024;1850:149393.
    PubMed         Abstract available

  18. XIE Y, Yang M, Wang H, Chen Y, et al
    Potential molecular mechanisms of tobacco smoke exposure in Alzheimer's disease.
    Brain Res. 2024;1848:149394.
    PubMed         Abstract available


    Curr Alzheimer Res

  19. GAO C, Pang X, Wang C, Huang J, et al
    Using Entropy as the Convergence Criteria of Ant Colony Optimization and the Application at Gene Chip Data Analysis.
    Curr Alzheimer Res. 2025;21:324-341.
    PubMed         Abstract available


    Dement Geriatr Cogn Disord

  20. CHOWDHURY D, Roy AK, Reddy VR, Gupta YK, et al
    Multicenter, Open-Label, Prospective Study Shows Safety and Therapeutic Benefits of a Defined Ginkgo Biloba Extract for Adults with Major Neurocognitive Disorder.
    Dement Geriatr Cogn Disord. 2024;53:299-309.
    PubMed         Abstract available


    Exp Gerontol

  21. AROSIO B, Picca A
    The biological roots of the sex-frailty paradox.
    Exp Gerontol. 2024;198:112619.
    PubMed         Abstract available

  22. RASHEED N, Hussain HK, Rehman Z, Sabir A, et al
    Co-administration of coenzyme Q10 and curcumin mitigates cognitive deficits and exerts neuroprotective effects in aluminum chloride-induced Alzheimer's disease in aged mice.
    Exp Gerontol. 2024;199:112659.
    PubMed         Abstract available


    Exp Neurol

  23. FRANKLIN Z, Hull C, Delibegovic M, Platt B, et al
    Pharmacological PTP1B inhibition rescues motor learning, neuroinflammation, and hyperglycaemia in a mouse model of Alzheimer's disease.
    Exp Neurol. 2024;385:115115.
    PubMed         Abstract available


    J Alzheimers Dis

  24. PEETHAMBARAN MALLIKA A
    Tri-culture modeling of neuroinflammation, neurodegeneration, and neuroprotection.
    J Alzheimers Dis. 2024;102:742-744.
    PubMed         Abstract available

  25. SOINIEMI L, Solje E, Suominen AL, Kanninen KM, et al
    The association between oral diseases and neurodegenerative disorders.
    J Alzheimers Dis. 2024;102:577-586.
    PubMed         Abstract available

  26. OKAFOR M, Yang Z, Vickers KL, Sanders K, et al
    Technology literacy and access to digital resources for remote assessment among adults enrolled in Alzheimer's disease research.
    J Alzheimers Dis. 2024 Dec 11:13872877241297496. doi: 10.1177/13872877241297496.
    PubMed         Abstract available

  27. ANDRES P, Flores-Vazquez JF, Enriquez-Geppert S
    Associating faces with names and meals as a biomarker of early AD in cognitively healthy individuals.
    J Alzheimers Dis. 2024;102:639-641.
    PubMed         Abstract available

  28. OLIVER A, Wildschut T, Redhead ES, Parker MO, et al
    Benefits of nostalgic landmarks for people living with Alzheimer's disease.
    J Alzheimers Dis. 2024;102:683-702.
    PubMed         Abstract available

  29. KISELICA AM, Atkinas KJ, Han SD, Diaz-Orueta U, et al
    Reactions of clinical neuropsychologists to the Alzheimer's Association workgroup's draft diagnostic and staging criteria for Alzheimer's disease.
    J Alzheimers Dis. 2024;102:877-884.
    PubMed         Abstract available

  30. CANEVELLI M, Ancidoni A, Valletta M, Toccaceli Blasi M, et al
    Reporting of comorbidities and health status of participants in clinical trials testing amyloid- and tau-targeting monoclonal antibodies for Alzheimer's disease: A systematic review.
    J Alzheimers Dis. 2024;102:587-596.
    PubMed         Abstract available

  31. NAZARETH CCG, Scalli ACAM, de Oliveira MPB, Gomes AFS, et al
    Differences in lean mass and sarcopenia between individuals with Alzheimer's disease and those without dementia: A systematic review and meta-analysis of observational studies.
    J Alzheimers Dis. 2024 Dec 16:13872877241299051. doi: 10.1177/13872877241299051.
    PubMed         Abstract available

  32. PLUTA R, Kocki J, Bogucki J, Bogucka-Kocka A, et al
    Apolipoprotein (APOA1, APOE, CLU) genes expression in the CA3 region of the hippocampus in an ischemic model of Alzheimer's disease with survival up to 2 years.
    J Alzheimers Dis. 2024 Dec 16:13872877241303950. doi: 10.1177/13872877241303950.
    PubMed         Abstract available

  33. GARCIA-LLUCH G, Marseglia A, Royo LM, Albiach JP, et al
    Associations between antidiabetic medications and cerebrospinal fluid biomarkers of Alzheimer's disease.
    J Alzheimers Dis. 2024 Dec 16:13872877241304995. doi: 10.1177/13872877241304995.
    PubMed         Abstract available

  34. BOADA M, Neve A, Das B, Wojtowicz J, et al
    Long-term safety of gantenerumab in participants with Alzheimer's disease: A phase III, open-label extension study (SCarlet RoAD).
    J Alzheimers Dis. 2024 Dec 16:13872877241303644. doi: 10.1177/13872877241303644.
    PubMed         Abstract available

  35. VIGNOLO J, Jacus JP, Darnaud T, Cuervo-Lombard CV, et al
    Exploratory study of French healthcare workers' experiences of anosognosia in Alzheimer's disease and related disorders.
    J Alzheimers Dis. 2024 Dec 19:13872877241307045. doi: 10.1177/13872877241307045.
    PubMed         Abstract available

  36. SHIR D, Shiner T, Bregman N
    Anti-amyloid treatments for Alzheimer's disease: A study on physicians' perspectives.
    J Alzheimers Dis. 2024;102:627-632.
    PubMed         Abstract available


    J Biol Chem

  37. MATSUMOTO M, Gomez-Soler M, Lombardi S, Lechtenberg BC, et al
    Missense Mutations of the Ephrin Receptor EPHA1 Associated with Alzheimer's Disease Disrupt Receptor Signaling Functions.
    J Biol Chem. 2024 Dec 18:108099. doi: 10.1016/j.jbc.2024.108099.
    PubMed         Abstract available


    J Neurochem

  38. MENG J, Lei P
    Testing cognitive normal for Alzheimer's disease prediction.
    J Neurochem. 2025;169:e16272.
    PubMed         Abstract available

  39. TSERING W, de la Rosa A, Ruan IY, Philips JL, et al
    Preferential clustering of microglia and astrocytes around neuritic plaques during progression of Alzheimer's disease neuropathological changes.
    J Neurochem. 2025;169:e16275.
    PubMed         Abstract available

  40. HE Y, Zhu P, Gao S, Wu S, et al
    Identification of Alzheimer's disease susceptibility genes by integrating eight human brain single-cell transcriptomes with genome-wide association studies.
    J Neurochem. 2025;169:e16276.
    PubMed         Abstract available


  41. EXPRESSION OF CONCERN: Potent Anti-amyloidogenic and Fibril-destabilizing Effects of Polyphenols In Vitro: Implications for the Prevention and Therapeutics of Alzheimer's Disease.
    J Neurochem. 2025;169:e16285.
    PubMed        

  42. PFITZER J, Pinky PD, Perman S, Redmon E, et al
    Troriluzole rescues glutamatergic deficits, amyloid and tau pathology, and synaptic and memory impairments in 3xTg-AD mice.
    J Neurochem. 2025;169:e16215.
    PubMed         Abstract available

  43. ELSWORTHY RJ, Finelli MJ, Aqattan S, Dunleavy C, et al
    Altered metabolic function induced by Abeta-oligomers and PSEN1 mutations in iPSC-derived astrocytes.
    J Neurochem. 2025;169:e16267.
    PubMed         Abstract available


    J Neurol

  44. ERATNE D, Li QX, Lewis C, Dang C, et al
    Strong diagnostic performance of plasma ptau217 for CSF biomarker-defined young-onset Alzheimer disease in a diagnostically heterogeneous clinical cohort.
    J Neurol. 2024;272:25.
    PubMed         Abstract available

  45. RAPOSO PEREIRA F, Chaumon M, Dubois B, Bakardjian H, et al
    Recognition memory decline is associated with the progression to prodromal Alzheimer's disease in asymptomatic at-risk individuals.
    J Neurol. 2024;272:70.
    PubMed         Abstract available

  46. ZILIOLI A, Rosenberg A, Mohanty R, Matton A, et al
    Brain MRI volumetry and atrophy rating scales as predictors of amyloid status and eligibility for anti-amyloid treatment in a real-world memory clinic setting.
    J Neurol. 2024;272:84.
    PubMed         Abstract available


    J Neurol Neurosurg Psychiatry

  47. JUNG JH, Byun MS, Yi D, Ahn H, et al
    Telomere length, in vivo Alzheimer's disease pathologies and cognitive decline in older adults.
    J Neurol Neurosurg Psychiatry. 2024 Dec 12:jnnp-2024-334314.
    PubMed         Abstract available

  48. HAZAN J, Abel E, Rosa Grilo M, Alawode D, et al
    How well do plasma Alzheimer's disease biomarkers reflect the CSF amyloid status?
    J Neurol Neurosurg Psychiatry. 2024 Dec 18:jnnp-2024-334122.
    PubMed         Abstract available


    J Neurosci

  49. HOUCHOIS JR, Attwood JE
    The Challenges of Modulating Neuroinflammation in Alzheimer's Disease and Multiple Sclerosis with TREM2 Agonistic Antibodies.
    J Neurosci. 2024;44:e1869242024.
    PubMed        


    Lancet Neurol

  50. THE LANCET NEUROLOGY
    Bridging the diagnostic gap in Alzheimer's disease.
    Lancet Neurol. 2025;24:1.
    PubMed        


    Nat Med

  51. MOGUILNER S, Baez S, Hernandez H, Migeot J, et al
    Brain clocks capture diversity and disparities in aging and dementia across geographically diverse populations.
    Nat Med. 2024;30:3646-3657.
    PubMed         Abstract available


    Nature

  52. KANG K, Seidlitz J, Bethlehem RAI, Xiong J, et al
    Study design features increase replicability in brain-wide association studies.
    Nature. 2024;636:719-727.
    PubMed         Abstract available


    Neurobiol Aging

  53. BERNARDO AM, Marcotte M, Wong K, Sharmin D, et al
    Procognitive and neurotrophic benefits of alpha5-GABA-A receptor positive allosteric modulation in a beta-amyloid deposition mouse model of Alzheimer's disease pathology.
    Neurobiol Aging. 2024;147:49-59.
    PubMed         Abstract available

  54. VERONELLI L, Tosi G, Romano D
    Modeling functional loss in Alzheimer's Disease through cognitive reserve and cognitive state: A panel data longitudinal study.
    Neurobiol Aging. 2024;147:60-67.
    PubMed         Abstract available


    Neurochem Res

  55. SMAIL SW
    Targeting Neuroinflammation and Apoptosis: Cardamonin's Cognitive Benefits in Alzheimer's 5XFAD Mice.
    Neurochem Res. 2024;50:57.
    PubMed         Abstract available


    Neurology

  56. RODRIGUEZ-BAZ I, Benejam B, Morcillo-Nieto AO, Vaque-Alcazar L, et al
    Posterior Cortical Atrophy Due to Alzheimer Disease in a Person With Down Syndrome: A Case Report.
    Neurology. 2025;104:e210179.
    PubMed         Abstract available


  57. Association of Seizure Foci and Location of Tau and Amyloid Deposition and Brain Atrophy in Patients With Alzheimer Disease and Seizures.
    Neurology. 2025;104:e210173.
    PubMed        

  58. LEE S, Rajmohan R, Al-Darsani Z, Paganini-Hill A, et al
    Medical Histories Associated With Absence of Alzheimer Disease Neuropathologic Changes in the Oldest-Old: The 90+ Study.
    Neurology. 2025;104:e210107.
    PubMed         Abstract available

  59. GRILL JD, Tam S, Thai G, Vides B, et al
    Phase 2A Proof-of-Concept Double-Blind, Randomized, Placebo-Controlled Trial of Nicotinamide in Early Alzheimer Disease.
    Neurology. 2025;104:e210152.
    PubMed         Abstract available


    Neuroscience

  60. LI C, Wang S, Xia Y, Shi F, et al
    Risk factors and predictive models in the progression from MCI to Alzheimer's disease.
    Neuroscience. 2024;565:312-319.
    PubMed         Abstract available

  61. FANG H, Tian H, Liu J, Peng T, et al
    Ginsenoside Rg1 attenuates Abeta(1-42)-induced microglial cell apoptosis and inflammation in Alzheimer's disease via the GATA4/PDE4A/PI3K/AKT axis.
    Neuroscience. 2024;565:377-385.
    PubMed         Abstract available

  62. APARAJITA A, Jain U, Srivastava P
    "Current and emerging drug therapies in Alzheimer's disease: A pathophysiological Perspective".
    Neuroscience. 2024;565:499-518.
    PubMed         Abstract available

  63. WOOD OWG, Yeung JHY, Palpagama TH, Turner C, et al
    Upregulated excitatory amino acid transporter 1 (EAAT1) expression in the human medial temporal lobe in Alzheimer's disease.
    Neuroscience. 2024 Dec 16:S0306-4522(24)00734.
    PubMed         Abstract available


    PLoS One

  64. ALROUJI M, Yasmin S, Alshammari MS, Alhumaydhi FA, et al
    Unveiling Cathepsin B inhibition with repurposed drugs for anticancer and anti-Alzheimer's drug discovery.
    PLoS One. 2024;19:e0316010.
    PubMed         Abstract available

  65. MUSA MS, Islam MT, Billah W, Hossain MS, et al
    Structure-based virtual screening of Trachyspermum ammi metabolites targeting acetylcholinesterase for Alzheimer's disease treatment.
    PLoS One. 2024;19:e0311401.
    PubMed         Abstract available

  66. SAEED A, Waris A, Fuwad A, Iqbal J, et al
    Random survival forest model for early prediction of Alzheimer's disease conversion in early and late Mild cognitive impairment stages.
    PLoS One. 2024;19:e0314725.
    PubMed         Abstract available

  67. YANG X, Fan Z, Li Z, Zhou J, et al
    Resting-state EEG microstate features for Alzheimer's disease classification.
    PLoS One. 2024;19:e0311958.
    PubMed         Abstract available

  68. SHIM SR, Kim JY, Kwon KY, Shin J, et al
    Effects of rivastigmine on gait in patients with neurodegenerative disorders: A systematic review and meta-analysis.
    PLoS One. 2024;19:e0310900.
    PubMed         Abstract available

  69. SHINOMOTO M, Takeuchi C, Tatebe H, Kitani-Morii F, et al
    Comparison between DSQIID total / sub-item scores and plasma p-tau elevation in adults with Down's syndrome.
    PLoS One. 2024;19:e0311878.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  70. CHAKRABORTY P, Ibanez de Opakua A, Purslow JA, Fromm SA, et al
    GSK3beta phosphorylation catalyzes the aggregation of tau into Alzheimer's disease-like filaments.
    Proc Natl Acad Sci U S A. 2024;121:e2414176121.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Alzheimer's Disease is free of charge.